Ideayas

sutthirat sutthisumdang Cantor Fitzgerald said it sees Tango Therapeutics (NASDAQ:TNGX) benefitting from Ideaya’s (IDYA) positive Phase 2 data for its MAT2A inhibitor IDE397 in the treatment of non-small cell lung and urothelial cancers. The investment bank noted that IDE397 works on the same pathway as Tango’s PRMT5 inhibitors TNG462 andContinue Reading